If you don’t already count EMD Serono among the leaders in research of multiple sclerosis treatments in the Boston area, perhaps you haven’t talked to EMD chief executive Fereydoun Firouz. For EMD Serono—the U.S. affiliate of German chemical and drug powerhouse Merck KGaA and its Swiss biotech unit Merck Serono— the Boston area is home to a multi-pronged effort to develop new drugs for multiple sclerosis as well as other neurodegenerative diseases, cancer, and fertility-related conditions.
Ryan McBride6/8/09
If you don’t already count EMD Serono among the leaders in research of multiple sclerosis treatments in the Boston area, perhaps you haven’t talked to EMD chief executive Fereydoun Firouz. For EMD Serono—the U.S. affiliate of German chemical and drug powerhouse Merck KGaA and its Swiss biotech unit Merck Serono— the Boston area is home to a multi-pronged effort to develop new drugs for multiple sclerosis as well as other neurodegenerative diseases, cancer, and fertility-related conditions.
Click here to continue reading============================================